IRCCS Humanitas Research Hospital
- Address
- lock Available on a paid plan
IRCCS Humanitas Research Hospital
IRCCS Humanitas Research Hospital is a distinguished Italian research institution conducting cutting-edge clinical trials across multiple therapeutic domains. The center demonstrates particular expertise in cardiovascular medicine, nephrology, and hematologic disorders, with a strong focus on developing innovative treatment strategies for complex medical conditions.
- Cardiovascular thromboembolism and anticoagulation therapy for stress-induced atrial fibrillation
- Kidney disease management, specifically IgA nephropathy with targeted biopsy-guided therapeutic approaches
- Hematologic malignancies and anemia treatment in myelodysplastic syndromes with chromosomal deletions
The research center's work encompasses advanced investigations into non-vitamin K oral anticoagulants (NOACs) for stroke prevention, precision medicine approaches using kidney biopsy-guided therapy in nephrology, and novel agents like luspatercept for transfusion-dependent anemia. Their trials emphasize personalized treatment strategies, comparing standard care with innovative therapeutic interventions to optimize patient outcomes while minimizing adverse effects across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 31 therapeutic areas and 15 of 714 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 673 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 171 by active trials.
- 1AstraZeneca AB32active
lock +170 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB63trials
lock +98 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in IRCCS Humanitas Research Hospital
lock Showing 1 of 760 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 714 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 57 | Unknown | 2016-02-02 | 2026-07-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.